Can liothyronine therapy lower free T4 and contribute to persistent hypothyroid symptoms?

Clinical and physiological evidence

• HPT axis suppression: Exogenous liothyronine (T3) therapy exerts potent negative feedback on the hypothalamic-pituitary-thyroid (HPT) axis. Pituitary thyrotropin (TSH) secretion is highly sensitive to thyroid hormone levels, and exogenous T3 directly suppresses TSH production by providing a robust feedback signal at the hypothalamus and pituitary.
• Reduction of circulating free T4: Clinical trials and physiological studies demonstrate that liothyronine therapy consistently reduces circulating free T4 (FT4) levels. This occurs because the T3-mediated suppression of TSH downregulates endogenous thyroidal production of T4, and because adding T3 clinically typically requires a reduction in the concomitantly administered levothyroxine (T4) dose.
• Substrate limitation: Circulating FT4 serves as the primary global prohormone substrate for intracellular uptake and subsequent local metabolic activation. When circulating FT4 levels are restricted (such as in the low-normal reference range), the available intracellular T4 substrate is directly limited in peripheral tissues.

Mechanistic explanations

• Impaired local conversion: Restricted intracellular T4 availability directly impairs tissue-specific, local T4-to-T3 conversion in organs that depend on type 2 deiodinase (D2/DIO2) for their active thyroid hormone supply, such as the brain, skeletal muscle, and brown adipose tissue. These tissues generate their intracellular T3 locally rather than equilibrating rapidly with circulating T3.
• Tissue hypothyroidism: This impairment in localized T3 production leads to a state of localized "tissue hypothyroidism." Standard serum thyroid panels (TSH and FT4) can appear biochemically "normal" or "euthyroid" while intracellular T3 levels remain insufficient.
• Genetic vulnerability: This intracellular T3 mismatch is compounded by genetic variations like the DIO2 Thr92Ala (T92A) polymorphism, which reduces the catalytic efficiency of the D2 enzyme, worsening local T3 deficiency despite conventional biochemical euthyroidism.

Bottom line

Liothyronine therapy suppresses TSH and lowers circulating free T4, which can restrict the essential prohormone substrate needed for local, intracellular T4-to-T3 conversion. This substrate limitation can cause localized tissue hypothyroidism and drive persistent clinical symptoms despite "normal" standard serum thyroid panels.